Novo Nordisk Trading Volume Drops 53.68% Ranking 162nd Amid Hims & Hers Dispute

On June 24, 2025, Novo Nordisk (NVO) saw a trading volume of 4.93 billion, a 53.68% decrease from the previous day, ranking 162nd in the day's stock market activity. The stock price of Novo Nordisk rose by 1.45%.

Novo Nordisk has terminated its partnership with Hims & Hers, citing concerns over the telehealth company's sale of counterfeit versions of the weight-loss drug Wegovy. This decision has significant implications for Novo Nordisk's market strategy and patient access to Wegovy. The Danish pharmaceutical company has emphasized its commitment to patient safety and has vowed to take action against any practices that jeopardize public health.

Novo Nordisk's decision to end its collaboration with Hims & Hers comes after allegations that the telehealth company continued to sell illicit compounded versions of Wegovy, which may not be as safe as the original product. This move has led to a reduction in patient access to Wegovy through the Hims & Hers platform, impacting Novo Nordisk's market share plans. The company has stated that it will continue to work with telehealth partners that prioritize patient safety and adhere to legal standards.

Hims & Hers has responded to Novo Nordisk's allegations, stating that the pharmaceutical company pressured them to prescribe Wegovy regardless of clinical necessity. The telehealth company has expressed disappointment in Novo Nordisk's actions and has refused to comply with what it perceives as anticompetitive demands. This dispute highlights the ongoing tension between pharmaceutical companies and telehealth providers over patient care and market control.